Summary
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
History
Allena Pharmaceuticals was founded in 2005 as an early-stage biopharmaceutical company and has since grown to become one of the top players in the space, with multiple clinical programs and 11 investigational drugs in development. Since its inception, Allena Pharmaceuticals has been awarded multiple grants from the National Institutes of Health to support its research and development.
Mission
At Allena Pharmaceuticals, we are driven to provide optimal therapies for patients with rare and severe metabolic and kidney disorders. We believe in developing innovative, safe and effective medicines for those who need them most.
Vision
Our vision is to improve the lives of people living with metabolic and kidney disorders. We strive to be a diverse and global leader in the research and development of novel therapeutics and companion diagnostics, while providing meaningful access to these products and services.
Key Team
Alex Thieme (Founder)
Alexey Margolin (Founder)
Robert Gallotto (Founder)
Recognition and Awards
Allena Pharmaceuticals has won a number of awards, including being named one of the 2019 DuPont Top 10 Pharmaceutical Pioneers, receiving the 2019 Scrip Award for Best Clinical Collaboration, and being named to Forbes 2019 Best Small Companies list.
References
